The panel discussion will cover the opportunities and challenges for molecular glues, which have gone from serendipitous discovery to rational design to the clinic in near-record time – and we're only scratching the surface of their potential.
We hope to see you in San Diego!
We’re hitting the road and heading to #AACR2026. There, CEO Markus Warmuth will join a panel of biopharma leaders pioneering proximity-induced therapies: bit.ly/4te6LQ2
Maciej Cabanski presents today at the 20th WRIB on biomarker modalities in the early development of MGDs for immune mediated diseases and oncology, highlighting advances in clinical biomarker strategies for targeted protein degradation.
It’s a reminder that the future of research depends on inviting people in early, encouraging them to stay curious, and making space for them to lead.
As we celebrate Women’s History Month, we’re inspired by the scientists of tomorrow and committed to expanding pathways into science.
We’re delighted to have volunteered with Science Club for Girls this month, supporting their mission to increase access to STEM education and empower the next generation of girls and gender-expansive youth to see themselves in science.
Today, we report business highlights and financial results for the fourth quarter and full year of 2025. Read more: bit.ly/47240Zf
The discussion covered Markus’ history as a drug developer, why he is such a believer in MGDs, and what success might mean for patient care and for the biopharma industry. Listen to the full episode here: bit.ly/4cHTXMK
Jonathan Grinstein of Inside Precision Medicine had a wide-ranging conversation with our CEO, Markus Warmuth, for the “Behind the Breakthroughs” podcast, highlighting how we expect 2026 to be a breakthrough year for Monte Rosa and molecular glue degraders.
Filip Janku, CMO, will field questions on Monte Rosa’s progress and programs during a fireside chat today at the Barclays 28th Annual Global Healthcare Conference. We hope you can join us! bit.ly/4umolCx
Autoimmune diseases affect millions, yet many individuals still lack effective treatment options. At Monte Rosa, we’re harnessing MGDs to expand what’s possible in autoimmune care.
Learn more this Autoimmune Awareness Month: bit.ly/409ianC
Our CEO, Markus Warmuth, will provide an overview on recent progress and clinical data from our pipeline programs, including our NEK7 and GSPT1-directed degraders, today at the TD Cowen Health Care Conference. bit.ly/3OAtyXb
We’re turning scientific insight into meaningful progress for heart health – advancing a new way to treat inflammation in ASCVD by targeting the NLRP3/NEK7 pathway upstream.
Our NEK7-directed molecular glue degrader, MRT-8102, is designed to stop NLRP3 activation at the source.
CMO, Filip Janku, comments on our updated MRT-2359 data, which supports initiation of a new Phase 2 study this year to evaluate MRT-2359 in combination with a second-generation AR inhibitor in mCRPC patients with AR mutations. bit.ly/4aO3E9B
Today, we announced updated, positive clinical data from an ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC). bit.ly/4aPUt8P
Activation of the NLRP3 inflammasome promotes plaque growth and destabilization, and NEK7 is central to NLRP3 inflammasome assembly.
This biology is increasingly recognized as a key driver of ASCVD – and a promising target for next-generation cardiovascular therapies.
It’s not “just” cholesterol. The role of inflammation in atherosclerotic cardiovascular disease (ASCVD) is gaining increased attention.
On International Day of Women and Girls in Science, we’re celebrating the individuals advancing scientific innovation. From Boston to Basel, women at Monte Rosa are turning insight into impact for patients and the next generation.
Learn more: bit.ly/4krQLX8
#February11
ASCVD affects 40M+ people in the U.S. and is the leading cause of death worldwide, yet many are unfamiliar with it. Caused by plaque buildup in the arteries, it can lead to heart attack and stroke.
This Heart Health Month, learn more from @americanheart.bsky.social: bit.ly/3LCK8o7
On #WorldCancerDay, we’re proud to stand #UnitedByUnique. At Monte Rosa, our paths into oncology may differ, but we’re united in pushing drug discovery forward with the goal to develop precision treatments for people living with cancer.
Learn more: bit.ly/4qfnEHW
ICYMI: Adam Cartwright presented findings at #KSAutoimmune26 on MRT-6160 in multiple immune-mediated disease models.
Thanks to @keystonesymposia.bsky.social for convening such a rich and engaging event.
View the presentation here: bit.ly/4bk9dP0
We present findings today at #KSAutoimmune26 highlighting VAV1’s key role in T/B cell function and the broad therapeutic potential of MRT-6160 across multiple immune-mediated diseases, including SLE, Sjögren’s disease, rheumatoid arthritis, IBD, and others.
New findings in @natsmb.nature.com challenge the current understanding of how neosubstrates bind cereblon. We show G3BP2 bypasses canonical rules of CRBN engagement & introduce ‘glueprints’ as a new way to potentially expand the MGD target space: go.nature.com/4jP23EJ
CMO, Filip Janku, comments on the future clinical plans for MRT-8102 based on the highly encouraging data we have observed so far in our ongoing Phase 1 study.
Read the full data release here: bit.ly/4pxGtWz
Today, we reported positive interim data from an ongoing Phase 1 study of MRT-8102. We believe these data support the potential of MRT-8102 to be an oral best-in-class therapeutic among agents targeting the NRLP3/IL-1/IL-6 pathway. bit.ly/4pxGtWz
Conference call and webcast presentation today, January 7, 2026, at 8:00 a.m. ET. A webcast of the presentation will be accessible via the “Events & Presentations” section of Monte Rosa’s website. bit.ly/4qa3m3d
Today, we announced positive interim data from an ongoing Phase 1 clinical study evaluating MRT-8102, a NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by the NLRP3 inflammasome, IL-1β, and IL-6.
In 2025, we made meaningful clinical progress, deepened scientific leadership through key publications, and expanded strategic collaborations.
Looking ahead, we are focused on rigorous science, purposeful execution, and delivering differentiated medicines for patients.
In 2025, we made meaningful clinical progress, deepened scientific leadership through key publications, and expanded strategic collaborations.
Looking ahead, we are focused on rigorous science, purposeful execution, and delivering differentiated medicines for patients.
This holiday season, our team came together to support our communities in meaningful ways. Volunteering side by side not only allows us to give back - it strengthens our collaboration and sense of purpose long after the day of service ends.
Today, we announced promising interim results from an ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with mCRPC.
CEO Markus Warmuth shares his perspective on the data.
bit.ly/3KL2raf
